［1］    Schmid BC，Oehler MK.New perspectives in ovarian cancer treatment［J］.Maturitas，2014，77:128-136.

［2］   Cannistra SA.Cancer of the ovary［J］.N Engl J Med，2004，351:2519-2529.

［3］   Kalia M.Personalized oncology: recent advances and future challenges［J］.Metabolism，2013，62(Suppl 1):S11-S14.

［4］   Johnatty SE，Beesley J，Gao B，et al.ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas［J］.Gynecol Oncol，2013，131:8-14.

［5］   Vella N，Aiello M，Russo AE，et al.'Genetic profiling' and ovarian cancer therapy (review) ［J］.Mol Med Rep，2011，4:771-777.

［6］   Tewari KS，Sill MW，Long HJ，et al.Improved survival with bevacizumab in advanced cervical cancer［J］.N Engl J Med，2014，370:734-743.

［7］   Gyanchandani R，Sano D，Ortega AMV，et al.Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma［J］.Oral Oncol，2013，49:761-770.

［8］   Suh DH，Kim JW，Kang S，et al.Major clinical research advances in gynecologic cancer in 2013［J］.J Gynecol Oncol，2014，25:236-248.

［9］    Schiavone MB，Bashir S，Herzog TJ.Biologic therapies and personalized medicine in gynecologic malignancies［J］.Obstet Gynecol Clin North Am，2012，39:131-144.

［10］    Sood AK，Coleman RL.Targeted therapy in gynecologic oncology: biology，strategy，and assessment［J］.Gynecol Oncol，2010，116:155-156.

（2014-11-30收稿）